Physicians must deploy specific tools in specific ways at specific times — adding to the time-consuming treatment costs.

NICE recommends SGLT-2 inhibitors with metformin at diagnosis, citing major cardiovascular, renal, and mortality benefits.

People diagnosed with type 2 diabetes before age 40 face a higher lifetime risk of heart and kidney problems, so may benefit from adding another type of medicine called a GLP-1 receptor agonist (such ...

Please provide your email address to receive an email when new articles are posted on . Care partners of deaf and hard-of-hearing people with diabetes discussed challenges with having to communicate ...

This report illustrates how providing vital diabetes medications to uninsured patients through a charitable medication distributor improves clinical outcomes. Objectives: This study examined the ...

Tandem Diabetes Care (NASDAQ:TNDM) reported record fourth-quarter and full-year 2025 results while outlining a major shift in ...

The new NICE guidance recommends that most people should now be offered metformin along with an SGLT-2 inhibitor from the start, while also advising that they get a slow-release formulation of ...